About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valion Bio, Inc. - Common stock (NQ:VBIO)

0.5311 +0.0011 (+0.21%)
Delayed Quote Updated: 10:23 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Valion Bio, Inc. - Common stock

< Previous 1 2 Next >
News headline image
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome ("GI-ARS"), after the announcement of positive safety findings Fully funded study will evaluate... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
AFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a planned, fully funded therapeutic study evaluating survival and... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Interim CEO Dean Zikria's initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company's... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR ™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale... 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and... 
From Valion Bio, Inc.
Via ACCESS Newswire
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod program Next study will test whether the formulation delivers measurable amounts of Entolimod... 
From Valion Bio, Inc.
Via ACCESS Newswire
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Nasdaq confirms compliance with continued listing standard and closes the matter 
From Valion Bio, Inc.
Via ACCESS Newswire
News headline image
Valion Bio Announces Changes to Management and Board of Directors
From Valion Bio, Inc.
Via ACCESS Newswire
Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Valion Bio Announces Reverse Stock Split
From Valion Bio, Inc.
Via ACCESS Newswire
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
Top movers in Monday's session ↗
Via Chartmill
Monday's session: most active stocks ↗
Via Chartmill
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
Friday's session: most active stocks ↗
Via Chartmill
News headline image
Kartoon Studios (NYSE: TOON) Enters Next Growth Phase; Reports Q2 Revenue of $5.82M, EPS of $0.38 and $40.5M Cash Position – Plus More in Focus
Via AB Newswire
Topics Intellectual Property
These stocks have an unusual volume in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
From Valion Bio, Inc.
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.